SLIMALUMA HOME
CARALLUMA FIMBRIATA
HUMAN CLINICAL STUDIES
SAFETY STUDIES
CERTIFICATIONS FOR SLIMALUMA
PRESS RELEASES
ARTICLES IN PRESS ABOUT SLIMALUMA
 
     
     
  Acute Toxicity Study at St John's National Academy of Health Sciences, India  
     
  An acute toxicity study on Wistar rats was done, under OECD guidelines, using a very high dose of 5 g per kg body weight. No mortality or toxicity was observed.  
     
  No mortality was observed following the administration at a very high dose of 5g/kg body weight. Body weight, feed and water intake in all the rats were comparable with that of the control.  
     
  Subchronic Oral Toxicity Study at Bombay College of Pharmacy, India
 
     
  A Subchronic Toxicity Study was done in Wistar Rats, under OECD guidelines, at 90 mg per kg bodyweight, which is equivalent to the recommended human dosage of 1 gram a day. No mortality or toxicity was observed.  
     
  Mutagenicity Study [ Ames Test ] at Intox Pvt. Ltd., India  
     
  Mutagenicity Study by Salmonella Typhimurium reverse mutation test was carried out as per the OECD guidelines. It was concluded that the product was non-Mutagenic in all the 5 strains of Salmonella Typhimurium.  
     
  The Toxicity studies on Slimaluma were presented at the 2006 Annual Meeting and Exposition of the American Association of Pharmaceutical Chemists in San Antonio, Texas, USA, held from 29th October to 2nd November 2006.
 
     
     
     
PRODUCTS
 
 
 
 
 
 
 
 
 
 
 
LOCATIONS
 
UNITED STATES
 
INDIA
 
CHINA
 
HONG KONG
 
SOUTH AFRICA
 
BOTSWANA
 
KUWAIT
 
   
  © Copyright 2005-2007. All rights reserved by Gencor Pacific Group.